Nourish, a nutrition care platform, has secured $70 million in Series B funding led by JP Morgan Asset Management's growth equity division, pushing the company's valuation past $1 billion. Founded in 2021, Nourish virtually connects patients to registered dietitians who deliver nutritional care covered by insurance. The company plans to use the new investment to continue growing its national presence and improving its technology.

Nourish was established in 2021 by childhood friends Aidan Dewar and Sam Perkins, along with Perkins' college friend, CTO Stephanie Liu, to address a gap in accessible nutrition support. When Nourish launched in October 2020, it was a surprise to many that it had already raised $115 million.

The company has rapidly grown to become the largest nutrition care platform on the market, boasting over 3,000 registered dietitians. We’ve built deep relationships with numerous health plans, employers, health systems, and provider groups. In so doing they have safely guided hundreds of thousands of patients through their practice.

Nourish’s app is packed with game-changing features. Log meals with the help of AI, get personalized feedback based on your wearable or lab data, connect with care teams through messaging, and even access meal delivery. The other 95% of Nourish’s patients already get care that is 100% insured.

Nourish CEO Aidan Dewar’s vision for the company’s integrated model put registered dietitians at the center of its care delivery strategy.

"They're the stars of the show, and we want to treat them as such." - Aidan Dewar

Nourish, which has recently opened a GLP-1 companion program, offering nutrition support with prescriptions. They have launched a new “off-ramp” program that allows patients to safely taper off the drugs and keep their progress while achieving real results. Analysis reveals that Nourish’s GLP-1 patients are losing an average of 33% more weight. This only occurs when they have access to nutritional support in addition to their medication. Nourish’s patients are less likely to stop treatment with GLP-1s because of side effects.

Dewar emphasized the increasing need for more accessible and patient-centered healthcare solutions.

"All of these things have led to patients taking their health into their own hands, and patients and payers both looking for solutions like this." - Aidan Dewar

Paris Heymann, co-managing partner at JP Morgan Growth Equity Partners, who initially invested in Nourish's Series A during his time at Index Ventures, noted the company's impressive growth trajectory.

"This is one of the fastest-growing companies we've seen at scale in a long time." - Paris Heymann